Table 5.
Ongoing NOAC Trials
| Clinical Conditions or Drugs | Trial Names (NCT) |
|---|---|
| Rheumatic mitral stenosis | INVICTUS (NCT02832544), DAVID-MS (NCT04045093) |
| Covert stroke and cognitive decline | BRAIN-AF (NCT02387229) |
| Early vs late strategy after ischemic stroke | TIMING (NCT02961348), ELAN (NCT03148457), OPTIMAS (NCT03759938) |
| Intracranial hemorrhage | ASPIRE (NCT03907046), ENRICH-AF (NCT03950076), PRESTIGE-AF (NCT03996772) |
| Embolic stroke of undetermined source | ARCADIA (NCT03192215) |
| End-stage renal disease | AXADIA-AFNET 8 (NCT02933697), SAFE-D (NCT03987711) |
| Device-detected AF or AHRE | ARTESiA (NCT01938248), SILENT (NCT02004509), NOAH-AFNET 6 (NCT02618577) |
| After successful ablation | ODIn-AF (NCT02067182), OCEAN (NCT02168829), |
| Left-atrial appendage occlusion | STROKECLOSE (NCT02830152), ASAP-TOO (NCT02928497), WAVECREST2 (NCT03302494), CLOSURE (NCT03463317), Occlusion-AF (NCT03642509), OPTION (NCT03795298) |
| Anti-diabetic drug (Metformin) | TRIM-AF (NCT03603912) |
| Anti-inflammatory drug (Colchicine) | IMPROVE-PVI Pilot (NCT04160117) |
| XIa inhibitors | |
| Asundexian | OCEANIC-AF (to be assigned) |
| Milvexian | To be determined |
AF = atrial fibrillation; AHRE = atrial high rate episode; ARCADIA = AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke; ARTESiA = Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation; ASAP-TOO = Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation; ASPIRE = Anticoagulation in ICH Survivors for Stroke Prevention and Recovery; AXADIA-AFNET 8 = Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease-Atrial Fibrillation Network 8; BRAIN-AF = Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF; CLOSURE = Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy; DAVID-MS = Dabigatran for Mitral Stenosis Atrial Fibrillation; ELAN = Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischemic Stroke Patients With Atrial fibrillatioN; ENRICH-AF = EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation; IMPROVE-PVI Pilot = Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation; INVICTUS = INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority; NCT = National Clinical Trial identifier; NOAH-AFNET 6 = Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes-Atrial Fibrillation Network 6; OCEAN = Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial; OCEANIC-AF = Oral faCtor Eleven A iNhibitor asundexIan as novel antithrombotiC - Atrial Fibrillation study; Occlusion-AF = Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation; ODIn-AF = Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation; OPTION = Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation; OPTIMAS = OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke; PRESTIGE-AF = PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation; SAFE-D = Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis; SILENT = Subclinical AtrIal FibrilLation and StrokE PreveNtion Trial; STROKECLOSE = Prevention of Stroke by Left Atrial Appendage Closure in Atrial Fibrillation Patients After Intracerebral Hemorrhage; TIMING = TIMING of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation; TRIM-AF = Targeting Risk Interventions and Metformin for Atrial Fibrillation; WAVECREST2 = WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2; XIa = activated factor XI; other abbreviation as in Table 3.